Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy
Article first published online: 24 DEC 2001
Volume 52, Issue 1, pages 1–9, January 2000
How to Cite
Janssen and Lamberts (2000), Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy . Clinical Endocrinology, 52: 1–9. doi: 10.1046/j.1365-2265.2000.00922.x
- Issue published online: 24 DEC 2001
- Article first published online: 24 DEC 2001
- Cited By
Poor glycaemic control in type 1 diabetes is associated with elevated serum IGFBP-1 levels and reduced rather than elevated serum IGF-I levels. Increasing age is accompanied by a further decrease in serum IGF-I levels as well as an increase in IGFBP-l levels in adult diabetic type 1 and type 2 subjects. This is especially observed in diabetic type 1 subjects with manifest microvascular complications. IGFBP-I has been proposed as one of the IGF-I inhibitors in the serum of diabetics. Lowered IGF-I and increased IGFBP-1 levels in the blood may thus result in decreased IGF-I bioavailability at the tissue level.
We hypothesize that the premature and progressive decline in serum IGF-I bioactivity during ageing in diabetics ultimately results in insufficient protective effects by IGF-I in the kidneys, eyes and neurones, and thus the progression of diabetic microvascular complications. If this hypothesis is proven to be right, treatment of diabetic patients with IGF-I (eventually complexed to IGFBPs) as an adjunct to insulin might prevent and not worsen the development of diabetic microvascular complications.